Quarterly Statement Of Cash Flows

BrightPath Biotherapeutics Co., Ltd. - Filing #7302244

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
As at
2023-03-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-537,786,000 JPY
-552,972,000 JPY
Depreciation
JPY
48,000 JPY
Impairment losses
JPY
1,406,000 JPY
Interest and dividend income
-47,000 JPY
-6,000 JPY
Decrease (increase) in trade receivables
-24,000 JPY
24,000 JPY
Increase (decrease) in trade payables
-4,000 JPY
-64,000 JPY
Other, net
9,140,000 JPY
86,468,000 JPY
Subtotal
-524,665,000 JPY
-464,436,000 JPY
Interest and dividends received
42,000 JPY
9,000 JPY
Income taxes paid
-1,900,000 JPY
-1,900,000 JPY
Net cash provided by (used in) operating activities
-520,584,000 JPY
-466,327,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
JPY
-1,454,000 JPY
Cash flows from financing activities
Proceeds from issuance of bonds
500,000,000 JPY
JPY
Redemption of bonds
-287,500,000 JPY
JPY
Net cash provided by (used in) financing activities
1,002,619,000 JPY
JPY
Net increase (decrease) in cash and cash equivalents
482,034,000 JPY
-467,781,000 JPY
Cash and cash equivalents
1,539,394,000 JPY
1,057,360,000 JPY
1,063,188,000 JPY
1,530,969,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.